Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.